Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSGeneric

SYNRIBO

OMACETAXINE MEPESUCCINATE

Standard Dose
3.5MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SYNRIBO is listed in Drugs@FDA under application 203585 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient OMACETAXINE MEPESUCCINATE Form and strength POWDER;SUBCUTANEOUS - 3.5MG/VIAL Sponsor TEVA PHARMS INTL Submission history Latest submission status date: 2021-05-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview SYNRIBO is listed in Drugs@FDA under application 203585 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient OMACETAXINE MEPESUCCINATE Form and strength POWDER;SUBCUTANEOUS - 3.5MG/VIAL Sponsor TEVA PHARMS INTL Submission history Latest submission status date: 2021-05-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.